In vivo assessment of bone quality in postmenopausal women with type 2 diabetes

Journal of Bone and Mineral Research

Volumn 29, Issue 4, 2014, Pages 787-795

  Farr, Joshua N ^a   Drake, Matthew T ^a   Amin, Shreyasee ^a   Melton III, L Joseph ^a   McCready, Louise K ^a   Khosla, Sundeep ^a  

^a Mayo Clinic College of Medicine   (United States)

Author keywords

BONE MATERIAL STRENGTH; BONE TURNOVER; HRPQCT; MICROINDENTATION TESTING; TYPE 2 DIABETES

Indexed keywords

25 HYDROXYVITAMIN D; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOLLITROPIN; GLYCOSYLATED HEMOGLOBIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PROTON PUMP INHIBITOR; SEROTONIN UPTAKE INHIBITOR; THIAZIDE DIURETIC AGENT;

ADULT; AGED; ANTHROPOMETRY; ARTICLE; BODY MASS; BONE DENSITY; BONE TURNOVER; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE DURATION; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FOLLITROPIN BLOOD LEVEL; FRAGILITY FRACTURE; HUMAN; HYPERTENSION; IN VIVO STUDY; KIDNEY DISEASE; MIDDLE AGED; NEUROPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; OSSIFICATION; OSTEOLYSIS; POROSITY; POSTMENOPAUSE; RETINOPATHY; RISK FACTOR; TIBIA; TRABECULAR BONE; VASCULAR DISEASE; VERY ELDERLY; BONE; CASE CONTROL STUDY; PATHOPHYSIOLOGY; PHOTON ABSORPTIOMETRY;

ABSORPTIOMETRY, PHOTON; AGED; BONE AND BONES; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MIDDLE AGED; POSTMENOPAUSE;

EID: 84897904635     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.2106     Document Type: Article

References (51)

1. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2011.
2. Shaw JE, Sicree RA, Zimmet PZ., Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010; 87 (1): 4-14.
3. Flegal KM, Carroll MD, Kit BK, Ogden CL., Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA. 2012; 307 (5): 491-7.
4. Schwartz AV, Sellmeyer DE, Ensrud KE, et al. Older women with diabetes have an increased risk of fracture: a prospective study. J Clin Endocrinol Metab. 2001; 86 (1): 32-8.
5. Strotmeyer ES, Cauley JA, Schwartz AV, et al. Nontraumatic fracture risk with diabetes mellitus and impaired fasting glucose in older white and black adults: the health, aging, and body composition study. Arch Intern Med. 2005; 165 (14): 1612-7.
6. Bonds DE, Larson JC, Schwartz AV, et al. Risk of fracture in women with type 2 diabetes: the Women's Health Initiative Observational Study. J Clin Endocrinol Metab. 2006; 91 (9): 3404-10.
7. Melton LJ, Leibson CL, Achenbach SJ, Therneau TM, Khosla S., Fracture risk in type 2 diabetes: update of a population-based study. J Bone Miner Res. 2008; 23: 1334-42.
8. Janghorbani M, Van Dam RM, Willett WC., Hu FB. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol. 2007; 166 (5): 495-505.
9. Vestergaard P., Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes-a meta-analysis. Osteoporos Int. 2007; 18: 427-44.
10. Strotmeyer ES, Cauley JA, Schwartz AV, et al. Diabetes is associated independently of body composition with BMD and bone volume in older white and black men and women: The Health, Aging, and Body Composition Study. J Bone Miner Res. 2004; 19 (7): 1084-91.
11. Schwartz AV, Vittinghoff E, Bauer DC, et al. Association of BMD,FRAX score with risk of fracture in older adults with type 2 diabetes. JAMA. 2011; 305 (21): 2184-92.
12. Dawson-Hughes B, Tosteson AN, Melton LJ 3rd, et al. Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporosis Int. 2008; 19 (4): 449-58.
13. Giangregorio LM, Leslie WD, Lix LM, et al. FRAX underestimates fracture risk in patients with diabetes. J Bone Miner Res. 2012; 27 (2): 301-8.
14. Leslie WD, Rubin MR, Schwartz AV, Kanis JA., Type 2 diabetes and bone. J Bone Miner Res. 2012; 27 (11): 2231-7.
15. Seeman E, Delmas PD., Bone quality-the material and structural basis of bone strength and fragility. N Engl J Med. 2006; 354 (21): 2250-61.
16. Chavassieux P, Seeman E, Delmas PD., Insights into material and structural basis of bone fragility from diseases associated with fractures: how determinants of the biomechanical properties of bone are compromised by disease. Endocr Rev. 2007; 28 (2): 151-64.
17. Bridges D, Randall C, Hansma PK., A new device for performing reference point indentation without a reference probe. Rev Sci Instrum. 2012; 83 (4): 044301.
18. Randall C, Bridges D, Guerri R, et al. Applications of a new hand-held reference point indentation instrument measuring bone material strength. J Med Devices. 2013; 7 (4): 410051-6.
19. Diez-Perez A, Guerri R, Nogues X, et al. Microindentation for in vivo measurement of bone tissue mechanical properties in humans. J Bone Miner Res. 2010; 25 (8): 1877-85.
20. Guerri-Fernandez RC, Nogues X, Quesada Gomez JM, et al. Microindentation for in vivo measurement of bone tissue material properties in atypical femoral fracture patients and controls. J Bone Miner Res. 2013; 28 (1): 162-8.
21. Ingle BM, Hay SM, Bottjer HM, Eastell R., Changes in bone mass and bone turnover following distal forearm fracture. Osteoporos Int. 1999; 10 (5): 399-407.
22. Executive summary: Standards of medical care in diabetes-2010. Diabetes Care. 2010; 33 (Suppl 1): S4-10.
23. Rocca WA, Yawn BP, St Sauver JL, Grossardt BR., Melton LJ 3rd. History of the Rochester Epidemiology Project: half a century of medical records linkage in a US population. Mayo Clin Proc. 2012; 87 (12): 1202-13.
24. Khosla S, Riggs BL, Atkinson EJ, et al. Effects of sex and age on bone microstructure at the ultradistal radius: a population-based noninvasive in vivo assessment. J Bone Miner Res. 2006; 21 (1): 124-31.
25. Nicks KM, Amin S, Atkinson EJ, et al. Relationship of age to bone microstructure independent of areal bone mineral density. J Bone Miner Res. 2012; 27 (3): 637-44.
26. Farr JN, Charkoudian N, Barnes JN, et al. Relationship of sympathetic activity to bone microstructure, turnover, and plasma osteopontin levels in women. J Clin Endocrinol Metab. 2012; 97 (11): 4219-27.
27. Rasoulian R, Raeisi Najafi A, Chittenden M, Jasiuk I., Reference point indentation study of age-related changes in porcine femoral cortical bone. J Biomech. 2013; 46 (10): 1689-96.
28. Aref M, Gallant MA, Organ JM, et al. In vivo reference point indentation reveals positive effects of raloxifene on mechanical properties following 6 months of treatment in skeletally mature beagle dogs. Bone. 2013; 56 (2): 449-53.
29. Gallant MA, Brown DM, Organ JM, Allen MR, Burr DB., Reference-point indentation correlates with bone toughness assessed using whole-bone traditional mechanical testing. Bone. 2013; 53 (1): 301-5.
30. Burghardt AJ, Issever AS, Schwartz AV, et al. High-resolution peripheral quantitative computed tomographic imaging of cortical and trabecular bone microarchitecture in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2010; 95 (11): 5045-55.
31. Shu A, Yin MT, Stein E, et al. Bone structure and turnover in type 2 diabetes mellitus. Osteoporos Int. 2012; 23 (2): 635-41.
32. Patsch JM, Burghardt AJ, Yap SP, et al. Increased cortical porosity in type 2 diabetic postmenopausal women with fragility fractures. J Bone Miner Res. 2013; 28 (2): 313-24.
33. Qiu S, Fyhrie DP, Palnitkar S, Rao DS., Histomorphometric assessment of Haversian canal and osteocyte lacunae in different-sized osteons in human rib. Anat Rec A Discov Mol Cell Evol Biol. 2003; 272 (2): 520-5.
34. Zebaze RMD, Ghasem-Zadeh A, Bohte A, et al. Intracortical remodelling and porosity in the distal radius and post-mortem femurs of women: a cross-sectional study. Lancet. 2010; 375: 1729-36.
35. Schwartz AV, Vittinghoff E, Sellmeyer DE, et al. Diabetes-related complications, glycemic control, and falls in older adults. Diabetes Care. 2008; 31 (3): 391-6.
36. Oei L, Zillikens MC, Dehghan A, et al. High bone mineral density and fracture risk in type 2 diabetes as skeletal complications of inadequate glucose control: the Rotterdam study. Diabetes Care. 2013; 36 (6): 1619-28.
37. Schwartz AV, Margolis KL, Sellmeyer DE, et al. Intensive glycemic control is not associated with fractures or falls in the ACCORD randomized trial. Diabetes Care. 2012; 35 (7): 1525-31.
38. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993; 329 (14): 977-86.
39. Loke YK, Singh S, Furberg CD., Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ. 2009; 180 (1): 32-9.
40. Fulzele K, Riddle RC, DiGirolamo DJ, et al. Insulin receptor signaling in osteoblasts regulates postnatal bone acquisition and body composition. Cell. 2010; 142 (2): 309-19.
41. Cortizo AM, Sedlinsky C, McCarthy AD, Blanco A, Schurman L., Osteogenic actions of the anti-diabetic drug metformin on osteoblasts in culture. Eur J Pharmacol. 2006; 536 (1-2): 38-46.
42. Walsh JS, Newman C, Eastell R., Heart drugs that affect bone. Trends Endocrinol Metab. 2012; 23 (4): 163-8.
43. Vestergaard P, Rejnmark L, Mosekilde L., Diabetes and its complications and their relationship with risk of fractures in type 1 and 2 diabetes. Calcif Tissue Int. 2009; 84 (1): 45-55.
44. Krakauer JC, McKenna MJ, Buderer NF, et al. Bone loss and bone turnover in diabetes. Diabetes. 1995; 44: 775-82.
45. Gerdhem P, Isaksson A, Akesson K, Obrant KJ., Increased bone density and decreased bone turnover, but no evident alteration of fracture susceptibility in elderly women with diabetes mellitus. Osteoporos Int. 2005; 16 (12): 1506-12.
46. Dobnig H, Piswanger-Solkner JC, Roth M, et al. Type 2 diabetes mellitus in nursing home patients: effects on bone turnover, bone mass, and fracture risk. J Clin Endocrinol Metab. 2006; 91 (9): 3355-63.
47. Manavalan JS, Cremers S, Dempster DW, et al. Circulating osteogenic precursor cells in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2012; 97 (9): 3240-50.
48. Manolagas SC., From estrogen-centric to aging and oxidative stress: a revised perspective of the pathogenesis of osteoporosis. Endocr Rev. 2010; 31 (3): 266-300.
49. Hamann C, Goettsch C, Mettelsiefen J, et al. Delayed bone regeneration and low bone mass in a rat model of insulin-resistant type 2 diabetes mellitus is due to impaired osteoblast function. Am J Physiol Endocrinol Metab. 2011; 301 (6): E1220-8.
50. Sroga GE, Vashishth D., Effects of bone matrix proteins on fracture and fragility in osteoporosis. Curr Osteoporos Rep. 2012; 10 (2): 141-50.
51. Tang SY, Allen MR, Phipps R, Burr DB, Vashishth D., Changes in non-enzymatic glycation and its association with altered mechanical properties following 1-year treatment with risedronate or alendronate. Osteoporos Int. 2009; 20 (6): 887-94.